Kringle Pharma, Inc.

Equities

4884

JP3270790003

Biotechnology & Medical Research

Delayed Japan Exchange Other stock markets 11:30:00 26/06/2024 am IST			5-day change	1st Jan Change
1,028 ^JPY	+2.39%		+30.13%	+36.70%

13/05	Kringle Pharma, Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2024	CI
09/02	Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024	CI

Kringle Pharma, Inc. Provides Consolidated Earnings Guidance for Year Ending September 30, 2023

December 01, 2022 at 12:00 pm IST

Kringle Pharma, Inc. provided consolidated earnings guidance for year ending September 30, 2023 . For the period, the company expected net sales of JPY 68 million, operating loss of JPY 993 million, loss of JPY 955 million and Basic loss per share of JPY 177.50 per basic share.

Latest news about Kringle Pharma, Inc.

Kringle Pharma, Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2024	13/05	CI
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024	09/02	CI
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024	28/11	CI
Kringle Pharma, Inc. Completes Its Pre-Ind (Investigation New Drug) Meeting with the U.S. Food and Drug Administration Regarding the Development Plan of Kp-100It, A Lyophilized Formulation of Recombinant Human Hgf, for the Potential Treatment of Acute Spinal Cord Injury	17/11	CI
Kringle's Preclinical Research Shows Encouraging Results for Dual Therapy Approach in Treating Acute Spinal Cord Injuries	31/23/31	MT
Kringle Pharma, Inc. Announces Publication of Preclinical Results from Joint Research with Keio University on Severe Spinal Cord Injury	30/23/30	CI
Kringle Pharma, Inc. Announces Last Patient Out in Phase 3 Study of KP-100IT for the Treatment of Acute Spinal Cord Injury	02/23/02	CI
Kringle Pharma, Inc. announced that it has received ¥1.242 million in funding from Barclays Bank PLC (Tokyo Branch)	04/23/04	CI
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023	30/23/30	CI
Kringle Pharma, Inc. announced that it expects to receive ¥1.242 million in funding from Barclays Bank PLC (Tokyo Branch)	14/23/14	CI
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023	30/23/30	CI
Kringle Pharma Completes Patient Enrollment for Acute Spinal Cord Injury Treatment	14/23/14	MT
Kringle Pharma, Inc. Announces Last Patient Enrolled in Phase Iii Study for the Treatment of Acute Spinal Cord Injury	13/23/13	CI
Kringle Pharma Files Patent Application for Spinal Cord Injury Treatment	14/23/14	MT
Kringle Pharma, Inc. Announces Patent Application Claims Priority for the Treatment of Chronic Spinal Cord Injury	13/23/13	CI
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023	28/23/28	CI
Bank of Japan's Dovish Policy Bolsters Japanese Shares; Shionogi Proceeds with Pediatric Trial of COVID-19 Vaccine	18/23/18	MT
Kringle Pharma Enrolls Initial Candidate in Clinical Study for Vocal Impairment Treatment	18/23/18	MT
Kringle Pharma, Inc. Announces First Patient Enrollment in Phase III Clinical Study for the Treatment of Vocal Fold Scar	17/23/17	CI
Kringle Pharma, Inc. Provides Update on Progress of Phase 3 Clinical Trial in Patients with Acute Spinal Cord Injury	13/23/13	CI
Kringle Pharma, Inc. Provides Consolidated Earnings Guidance for Year Ending September 30, 2023	01/22/01	CI
Japan Shares Turn Red on Tokyo Inflation, Protests Over China Lockdown; Shionogi Seeks COVID-19 Vaccine Approval	25/22/25	MT
Kringle Pharma Starts Clinical Trial for Treatment of Vocal Impairment; Shares Up 7%	25/22/25	MT
Kringle Pharma, Inc. Announces Initiation of Phase III Study of HGF in Vocal Fold Scar	24/22/24	CI
Kringle Pharma, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	14/22/14	CI

Chart Kringle Pharma, Inc.

Duration

Period

More charts

Company Profile

Kringle Pharma Inc is a Japan-based company mainly engaged in the development of pharmaceuticals. The Company is involved in the research and development of therapeutic agents for intractable diseases using hepatocyte growth factor (HGF) protein. HGF has versatile bioactivity that is responsible for tissue or organ regeneration and protection such as cell proliferation promotion, cell motility promotion, anti-apoptosis, morphogenesis induction, and angiogenesis. HGF has a therapeutic effect on chronic fibrotic diseases such as liver cirrhosis, chronic renal failure, pulmonary fibrosis and cardiomyopathy. HGFs target diseases are Atrophic lateral sclerosis (ALS), Acute renal impairment, Vocal scar and others. The Company is involved in the general new drug development processes such as basic research, non-clinical trials and manufacturing, clinical trials, approval application and authorization, marketing and expansion of indications.

Sector

Biotechnology & Medical Research

Calendar

11/11/2024 - Q4 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
KRINGLE PHARMA, INC.	+36.70%	4.27Cr
MODERNA, INC.	+38.36%	5.27TCr
LONZA GROUP AG	+38.82%	3.9TCr
IQVIA HOLDINGS INC.	-8.63%	3.85TCr
ALNYLAM PHARMACEUTICALS, INC.	+25.46%	3.04TCr
CELLTRION, INC.	-11.17%	2.64TCr
ICON PUBLIC LIMITED COMPANY	+11.44%	2.61TCr
UNITED THERAPEUTICS CORPORATION	+45.09%	1.42TCr
MEDPACE HOLDINGS, INC.	+32.93%	1.26TCr
BIO-TECHNE CORPORATION	-5.30%	1.15TCr

Other Biotechnology & Medical Research